KoBioLabs, Inc.
Founded in 2014 and listed on KOSDAQ in 2020, KoBioLabs develops microbiome-based therapeutics with its KBLP pipeline and Smartiome platform.
As of 2026-10-08, KoBioLabs, Inc. has 54 PubMed-indexed papers on record (counted by the MAA Company Index from its own matching of public databases).
Price
Change
Market cap
Products & technology
- WeeBiome probioticsDietary supplements targeting women's health, immunity, metabolic and mental health
Clinical trials
data.go.kr1 MFDS clinical trial authorisations · 2023 (Phase 2a 1)
- Phase 2aKBL6972023-04-21
12 trial sites
Global clinical trials
ClinicalTrials.gov · sponsor-matchedPhase 2 · Withdrawn · 2022-01 · NCT04898348
- A Study to Investigate Efficacy and Safety of KBL697 in Patients with Moderate Plaque Type Psoriasis
Phase 2 · Completed · 2021-11 · NCT04911751
Phase 1 · Completed · 2020-08 · NCT04307173
Phase 1 · Completed · 2019-10 · NCT04056130
R&D and key agreements
Source: DART corporate disclosure건선 치료 후보물질(프로그램명 미상) · 중등도 건선 · 임상 2상(미국 FDA IND 승인, CSR 수취) · Topline data in Dec 2023 and CSR in Dec 2024
KBLP-002 · 알레르기 질환(천식, 아토피피부염) · 호주 임상 1상 완료, 임상 2상 IND 신청 예정 · Licensed to SPH Sine Pharmaceutical for China, Taiwan, Hong Kong and Macau
KBLP-004 · 대사질환 · 비임상 · Preclinical results show weight loss and metabolic biomarker improvement via GLP-1 induction
KBLP-005 · 암(면역항암 병용 포함) · 비임상 탐색 · Screening candidate strains and active substances
KBLP-006 · 염증성 장질환 · 비임상 · Development started November 2020; clinical entry under consideration
KBLP-010 · 자폐 스펙트럼 장애 · 인체적용시험 · Human application trial conducted in pediatric autism spectrum disorder patients
KBLP-014 · 암(약물전달체계 활용) · 비임상 · Uses smart microbe-based drug delivery system; preparing biofoundry-based mass production
Key disclosures
KRX KIND via OpenDARTPublications
PubMed · affiliation-matched- Oral Administration of Lactiplantibacillus plantarum KBL396 Regulates Serum 5-Hydroxytryptamine and Gut Microbiota: Evidence from a Preclinical Mouse Model and a Randomized Controlled Human Trial.
Probiotics and antimicrobial proteins · 2026-05 · Myung W, Jang SJ, Lee G 외 12
- Lacticaseibacillus paracasei KBL382 contributes to the immunomodulation in THP-1 cells.
Journal of microbiology (Seoul, Korea) · 2026-02 · Kim M, Jo MJ, Park S 외 5
- Lactobacillus acidophilus KBL409 improves serum indoxyl sulfate via gut microbial changes in a human study.
NPJ science of food · 2026-02 · Jang SJ, Park S, Lee K 외 7
- Bifidobacterium stercoris KC84 attenuates IBS-D-like symptoms via modulation of serotonin-related pathways and dendritic cell-mediated IFN-β induction.
Current research in microbial sciences · 2026-01 · Song S, Han M, Moon K 외 8
- Limosilactobacillus fermentum KBL674 Alleviates Vaginal Candidiasis.
Probiotics and antimicrobial proteins · 2025-12 · Jang SJ, Jo EJ, Lee C 외 8
- Application of integrated in vitro fecal cultivation and 16S rRNA gene sequencing for optimizing beneficial gut microbiota combinations.
Journal of microbiological methods · 2025-11 · Hitayezu E, Mauliasari IR, Yu S 외 5
- Synergistic Modulation of the Gut-Brain-Immune Axis by a Dual Lactobacillus Combination in a Murine IBS Model.
Journal of microbiology and biotechnology · 2025-10 · Song L, Lee H, Choi JS 외 3
- Lactobacillus crispatus KBL693 alleviates atopic dermatitis symptoms through immune modulation.
Journal of microbiology (Seoul, Korea) · 2025-10 · Song S, Kim JH, Jang SJ 외 3
- Oral Administration of Limosilactobacillus reuteri KBL346 Ameliorates Influenza Virus A/PR8 Infection in Mouse.
Probiotics and antimicrobial proteins · 2025-10 · Choi D, Jang SJ, Choi S 외 5
- Strain-Specific Anti-Inflammatory Effects of Faecalibacterium prausnitzii Strain KBL1027 in Koreans.
Probiotics and antimicrobial proteins · 2025-06 · Seo B, Jeon K, Kim WK 외 3
Show 44 more publications
- Identification of new biomarkers of hepatic cancer stem cells through proteomic profiling.
Journal of liver cancer · 2025-03 · Choi SH, Lee HY, Yun SH 외 5
- Correction: Lactobacillus acidophilus KBL409 protects against kidney injury via improving mitochondrial function in mice with chronic kidney disease'.
European journal of nutrition · 2024-12 · Park J, Nam KH, Nam BY 외 11
- Gliocidin is a nicotinamide-mimetic prodrug that targets glioblastoma.
Nature · 2024-12 · Chen YJ, Iyer SV, Hsieh DC 외 13
- Lactobacillus acidophilus KBL409 protects against kidney injury via improving mitochondrial function with chronic kidney disease.
European journal of nutrition · 2024-09 · Park J, Nam KH, Nam BY 외 11
- Regulation of Tumor Microenvironment through YAP/TAZ under Tumor Hypoxia.
Cancers · 2024-08 · Choi SH, Kim DY
- Fermented Milk Containing Lacticaseibacillus rhamnosus SNU50430 Modulates Immune Responses and Gut Microbiota in Antibiotic-Treated Mice.
Journal of microbiology and biotechnology · 2024-06 · Yoon S, Park S, Jung SE 외 4
- Lactobacillus acidophilus KBL409 Ameliorates Atopic Dermatitis in a Mouse Model.
Journal of microbiology (Seoul, Korea) · 2024-02 · Kim WK, Jang YJ, Park S 외 4
- Enhancement of Immune Functions by Limosilactobacillus reuteri KBL346: In Vitro and In Vivo Studies.
International journal of molecular sciences · 2023-12 · Park C, Ji SY, Hwangbo H 외 8
- Lactobacillus rhamnosus KBL2290 Ameliorates Gut Inflammation in a Mouse Model of Dextran Sulfate Sodium-Induced Colitis.
Journal of microbiology (Seoul, Korea) · 2023-07 · Kim WK, Min SG, Kwon H 외 3
- Secreted Akkermansia muciniphila threonyl-tRNA synthetase functions to monitor and modulate immune homeostasis.
Cell host & microbe · 2023-06 · Kim SM, Park S, Hwang SH 외 23
- Anti-inflammatory activities of black raspberry seed ellagitannins and their structural effects on the stimulation of glucagon-like peptide-1 secretion and intestinal bitter taste receptors.
Food & function · 2023-05 · Kim RH, Lee GE, Lee K 외 3
- Distinct Changes in Microbiota-Mediated Intestinal Metabolites and Immune Responses Induced by Different Antibiotics.
Antibiotics (Basel, Switzerland) · 2022-12 · Yoon S, Lee G, Yu J 외 5
- Lactobacillus acidophilus KBL409 Reduces Kidney Fibrosis via Immune Modulatory Effects in Mice with Chronic Kidney Disease.
Molecular nutrition & food research · 2022-11 · Kim H, Nam BY, Park J 외 9
- Wnt-activating human skin organoid model of atopic dermatitis induced by Staphylococcus aureus and its protective effects by Cutibacterium acnes.
iScience · 2022-10 · Jung SY, You HJ, Kim MJ 외 3
- Co-administration of Lactobacillus gasseri KBL697 and tumor necrosis factor-alpha inhibitor infliximab improves colitis in mice.
Scientific reports · 2022-06 · Han DH, Kim WK, Lee C 외 4
- Dietary antigens suppress the proliferation of type 2 innate lymphoid cells by restraining homeostatic IL-25 production.
Scientific reports · 2022-05 · Lee M, Ko HJ, Hong SW 외 8
- Sputum Bacterial Metacommunities in Distinguishing Heterogeneity in Respiratory Health and Disease.
Frontiers in microbiology · 2022-01 · Si J, Choi Y, Raes J 외 2
- Revisiting the role of Akkermansia muciniphila as a therapeutic bacterium.
Gut microbes · 2022-01 · Si J, Kang H, You HJ 외 1
- Interaction effect between NAFLD severity and high carbohydrate diet on gut microbiome alteration and hepatic de novo lipogenesis.
Gut microbes · 2022-01 · Kang H, You HJ, Lee G 외 9
- Crystal structure of the nuclease and capping domain of SbcD from Staphylococcus aureus.
Journal of microbiology (Seoul, Korea) · 2021-06 · Lee J, Jo I, Ahn J 외 4
- Akkermansia muciniphila secretes a glucagon-like peptide-1-inducing protein that improves glucose homeostasis and ameliorates metabolic disease in mice.
Nature microbiology · 2021-05 · Yoon HS, Cho CH, Yun MS 외 11
- Synthetic gut microbiome: Advances and challenges.
Computational and structural biotechnology journal · 2021-01 · Mabwi HA, Kim E, Song DG 외 5
- Gut microbiome signatures distinguish type 2 diabetes mellitus from non-alcoholic fatty liver disease.
Computational and structural biotechnology journal · 2021-01 · Si J, Lee G, You HJ 외 6
- Clostridium fessum sp. nov., isolated from human faeces.
International journal of systematic and evolutionary microbiology · 2021-01 · Seo B, Jeon K, Baek I 외 3
- Lactobacillus paracasei KBL382 administration attenuates atopic dermatitis by modulating immune response and gut microbiota.
Gut microbes · 2020-11 · Kim WK, Jang YJ, Han DH 외 4
- Improvement in host metabolic homeostasis and alteration in gut microbiota in mice on the high-fat diet: A comparison of calcium supplements.
Food research international (Ottawa, Ont.) · 2020-10 · Cha KH, Yang JS, Kim KA 외 6
- Distinct signatures of gut microbiome and metabolites associated with significant fibrosis in non-obese NAFLD.
Nature communications · 2020-10 · Lee G, You HJ, Bajaj JS 외 10
- Lactobacillus paracasei treatment modulates mRNA expression in macrophages.
Biochemistry and biophysics reports · 2020-09 · Han DH, Kim WK, Park S 외 2
- Real-Time Measurement of the Liquid Amount in Cryo-Electron Microscopy Grids Using Laser Diffraction of Regular 2-D Holes of the Grids.
Molecules and cells · 2020-03 · Ahn J, Lee D, Jo I 외 5
- Roseburia spp. Abundance Associates with Alcohol Consumption in Humans and Its Administration Ameliorates Alcoholic Fatty Liver in Mice.
Cell host & microbe · 2020-01 · Seo B, Jeon K, Moon S 외 11
- Crystal Structure of the Regulatory Domain of MexT, a Transcriptional Activator of the MexEFOprN Efflux Pump in Pseudomonas aeruginosa.
Molecules and cells · 2019-12 · Kim S, Kim SH, Ahn J 외 4
- Faecalibacillus intestinalis gen. nov., sp. nov. and Faecalibacillus faecis sp. nov., isolated from human faeces.
International journal of systematic and evolutionary microbiology · 2019-07 · Seo B, Jeon K, Baek I 외 3
- Vaginal lactobacilli inhibit growth and hyphae formation of Candida albicans.
Scientific reports · 2019-05 · Jang SJ, Lee K, Kwon B 외 2
- Lactobacillus fermentum species ameliorate dextran sulfate sodium-induced colitis by regulating the immune response and altering gut microbiota.
Gut microbes · 2019-01 · Jang YJ, Kim WK, Han DH 외 2
- Administration of Lactobacillus fermentum KBL375 Causes Taxonomic and Functional Changes in Gut Microbiota Leading to Improvement of Atopic Dermatitis.
Frontiers in molecular biosciences · 2019-01 · Kim WK, Jang YJ, Han DH 외 4
- Effects of fermented milk treatment on microbial population and metabolomic outcomes in a three-stage semi-continuous culture system.
Food chemistry · 2018-10 · Cha KH, Lee EH, Yoon HS 외 7
- Bile salt hydrolase-mediated inhibitory effect of Bacteroides ovatus on growth of Clostridium difficile.
Journal of microbiology (Seoul, Korea) · 2017-11 · Yoon S, Yu J, McDowell A 외 3
- Molecular and clinical characterization of human respiratory syncytial virus in South Korea between 2009 and 2014.
Epidemiology and infection · 2017-11 · Park E, Park PH, Huh JW 외 5
- Merdimonas faecis gen. nov., sp. nov., isolated from human faeces.
International journal of systematic and evolutionary microbiology · 2017-07 · Seo B, Yoo JE, Lee YM 외 1
- Airborne Bacterial Communities in Three East Asian Cities of China, South Korea, and Japan.
Scientific reports · 2017-07 · Lee JY, Park EH, Lee S 외 6
- Modeling environmental risk factors of autism in mice induces IBD-related gut microbial dysbiosis and hyperserotonemia.
Molecular brain · 2017-04 · Lim JS, Lim MY, Choi Y 외 1
- Evaluation of Various Real-Time Reverse Transcription Quantitative PCR Assays for Norovirus Detection.
Journal of microbiology and biotechnology · 2017-04 · Yoo JE, Lee C, Park S 외 1
- Complete Genome Sequence of the Plasmid-Bearing Lactobacillus fermentum Strain SNUV175, a Probiotic for Women's Health Isolated from the Vagina of a Healthy South Korean Woman.
Genome announcements · 2017-03 · Lee S, You HJ, Kwon B 외 1
- Complete Genome Sequence of Lactobacillus jensenii Strain SNUV360, a Probiotic for Treatment of Bacterial Vaginosis Isolated from the Vagina of a Healthy Korean Woman.
Genome announcements · 2017-03 · Lee S, You HJ, Kwon B 외 1
Patents
KIPRIS · applicant-matched- Subsidiary: 주식회사 위바이옴다중 코팅된 프로바이오틱스 및 이의 제조방법
Registered · 2026-04 · Application 1020260063955
Registered · 2025-12 · Application 1020250214847
PCT · Published · 2025-09 · Application PCT/KR2025/015305
Registered · 2025-09 · Application 1020250135547
PCT · Published · 2025-09 · Application PCT/KR2025/013680
Published · 2025-09 · Application 1020250126034
Registered · 2025-05 · Application 1020250065755
US · Published · 2025-05 · Application 19204807
Published · 2025-05 · Application 1020250059387
- Subsidiary: 주식회사 위바이옴IMMUNITY ENHANCEMENT USE OF LACTOBACILLUS FERMENTUM STRAIN
PCT · Published · 2025-04 · Application PCT/KR2025/005191
Show 90 more patents
PCT · Published · 2025-03 · Application PCT/KR2025/095110
Registered · 2025-03 · Application 1020250038212
PCT · Published · 2025-01 · Application PCT/KR2025/001502
PCT · Published · 2025-01 · Application PCT/KR2025/001523
Registered · 2024-12 · Application 1020240194675
Published · 2024-09 · Application 1020240132026
PCT · Published · 2024-09 · Application PCT/KR2024/014395
PCT · Published · 2024-06 · Application PCT/KR2024/008198
US · Published · 2024-02 · Application 19156131
PCT · Published · 2024-02 · Application PCT/KR2024/002112
PCT · Published · 2024-02 · Application PCT/KR2024/002109
Registered · 2024-02 · Application 1020240021351
Registered · 2024-02 · Application 1020240021350
Published · 2024-01 · Application 1020240012704
Registered · 2024-01 · Application 1020240012705
Registered · 2024-01 · Application 1020240006730
Registered · 2023-10 · Application 1020230141533
Published · 2023-07 · Application 1020230088545
Registered · 2023-01 · Application 1020230001737
US · Registered · 2022-10 · Application 18050091
PCT · Published · 2022-10 · Application PCT/KR2022/016092
PCT · Published · 2022-10 · Application PCT/KR2022/016090
Registered · 2022-10 · Application 1020220135952
Registered · 2022-10 · Application 1020220135948
US · Registered · 2022-02 · Application 17673460
US · Registered · 2022-02 · Application 17673488
Registered · 2022-02 · Application 1020220019985
Withdrawn · 2021-11 · Application 1020210152464
PCT · Published · 2021-10 · Application PCT/KR2021/013946
US · Registered · 2021-09 · Application 17448620
TW · Registered · 2021-08 · Application 110129969
US · Published · 2021-08 · Application 18041369
EP · Published · 2021-08 · Application 21856275.9
PCT · Published · 2021-08 · Application PCT/KR2021/010768
Published · 2021-08 · Application 1020210106930
PCT · Published · 2021-05 · Application PCT/KR2021/006314
US · Published · 2021-04 · Application 17996956
EP · Published · 2021-04 · Application 21792888.6
PCT · Published · 2021-04 · Application PCT/KR2021/005036
Rejected · 2021-04 · Application 1020210051795
Registered · 2020-12 · Application 1020200165733
Registered · 2020-12 · Application 1020200165732
US · Registered · 2020-11 · Application 17102301
US · Registered · 2020-11 · Application 17093556
US · Published · 2020-09 · Application 17765972
US · Registered · 2020-09 · Application 17019677
US · Registered · 2020-07 · Application 17626628
US · Published · 2020-07 · Application 17626632
EP · Published · 2020-07 · Application 20848228.1
EP · Published · 2020-07 · Application 20848579.7
PCT · Published · 2020-07 · Application PCT/KR2020/010097
PCT · Published · 2020-07 · Application PCT/KR2020/010092
Registered · 2020-07 · Application 1020200094922
Expired · 2020-07 · Application 1020200095361
Withdrawn · 2020-07 · Application 1020200087105
Rejected · 2020-06 · Application 1020200066313
US · Registered · 2019-10 · Application 17279247
EP · Published · 2019-10 · Application 19871795.1
PCT · Published · 2019-10 · Application PCT/KR2019/013402
Registered · 2019-10 · Application 1020190125670
Registered · 2019-10 · Application 1020190122531
EP · Published · 2019-05 · Application 19806947.8
Registered · 2019-05 · Application 1020190060905
Registered · 2019-05 · Application 1020190060904
EP · Published · 2019-05 · Application 26156649.1
EP · Registered · 2019-05 · Application 19798873.6
EP · Published · 2019-05 · Application 26156636.8
Registered · 2019-05 · Application 1020190054252
PCT · Published · 2019-04 · Application PCT/KR2019/004790
US · Registered · 2019-02 · Application 16962976
EP · Published · 2019-02 · Application 19747730.0
Registered · 2019-02 · Application 1020190014501
CN · Published · 2018-09 · Application 201880076591.7
US · Registered · 2018-09 · Application 16648358
EP · Published · 2018-09 · Application 18860264.3
Registered · 2018-09 · Application 1020180115823
Registered · 2018-04 · Application 1020180045772
Registered · 2018-01 · Application 1020180003582
PCT · Published · 2017-11 · Application PCT/KR2017/013498
Registered · 2017-11 · Application 1020170158315
Registered · 2017-09 · Application 1020170122620
Registered · 2017-09 · Application 1020170122608
US · Registered · 2017-07 · Application 16316662
EP · Published · 2017-07 · Application 17834703.5
PCT · Published · 2017-07 · Application PCT/KR2017/007841
Registered · 2017-03 · Application 1020170041922
Registered · 2016-07 · Application 1020160094299
US · Published · 2016-03 · Application 15566352
PCT · Published · 2016-03 · Application PCT/KR2016/002988
Registered · 2016-02 · Application 1020160022840
AI reads
MAA server logs · IP-verifiedPulled records become part of each AI's index and keep feeding its answers. When an AI cites from that index, nothing reaches our server — so actual citations are uncounted here and exceed this number.
Times an AI needed something not yet in its index and fetched this page fresh while answering. Citations served from the index leave no trace here.
Collected as raw material for future answers.
Queries from users who connected this index to their own AI.
- OpenAIOAI-SearchBot6
- PerplexityPerplexityBot2
- AnthropicClaudeBot2
- MicrosoftBingbot1
- GoogleGoogleOther1
Measured since Aug 27, 2026 · 5 AI engines · last read Sep 29, 2026
User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS. MCP queries are actual calls to this index's tool endpoint.
Connect this company index directly to your AI
Connect it to ChatGPT or Claude, and your AI queries the full record — profiles, financials, stock data, regulatory approvals, clinical trials, publications and patents — for KoBioLabs, Inc. and every listed Korean medical, bio and AI company.
How to connect (MCP)Companies in the same categoryBiotech & Drug Discovery
KOSDAQ-listed integrated security company behind the V3 antivirus and AhnLab TrusGuard and XDR solutions.
Drug delivery system company behind the long-acting injectable platform IVL-DrugFluidic and the LNP delivery platform IVL-GeneFluidic.
Organoid-based biotech founded 2018, KOSDAQ-listed 2025, developing the ATORM-C regenerative therapeutic and ODISEI evaluation solution.
EDGC, a Korea-US joint venture of Eone Medical Foundation and Diagnomics, offers the NIPT service NICE and liquid biopsy OncoCatch.
A diversified SK group company operating eco-friendly chemical materials alongside pharmaceutical products like Joins and vaccines through subsidiary SK Bioscience.
Genomics and drug developer behind the osteoarthritis drug Acelex and the AI-driven healthcare platform Invites Loop.
KOSDAQ-listed antibody biotech developing the next-generation immuno-oncology candidate Multi-AbKine on its fully human antibody library Ymax®-ABL.
A holding company overseeing 54 affiliates including its main biopharmaceutical subsidiary GC, with no direct product manufacturing of its own.
Founded in 2015 and listed on KOSPI in 2021, Prestige BioPharma develops antibody biosimilars and novel antibody drugs including Tuznue.
KOSDAQ-listed biotech company developing molecular diagnostics with proprietary C-Tag technology and the NeoPlex product line.
SillaJen, Inc., founded in 2006 and listed on KOSDAQ in 2016, develops the oncolytic virus immunotherapy Pexa-Vec.
A vaccine specialist developing in-house products such as SKYCellflu and SKYZoster while also serving as CDMO for AstraZeneca and Novavax.
Sources and updates
Counts on this page are not company-reported figures. MAA matched records from DART, the Korean MFDS, the US FDA, ClinicalTrials.gov, PubMed and KIPRIS to this company itself, by business registration number or registered name, never by name similarity. They may differ from figures the company publishes.
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- Approvals & clinical trials
- Korean MFDS (data.go.kr) · US FDA openFDA — updated weekly
- Key disclosures
- KRX KIND via OpenDART exchange filings — updated daily
- Global clinical trials
- ClinicalTrials.gov (US NIH) — sponsor-matched, updated weekly
- Financials
- DART corporate disclosure filings — annual
- Publications
- PubMed (US National Library of Medicine) — affiliation-matched, updated daily
- Patents
- KIPRIS (Korea Institute of Patent Information) — applicant-matched, updated monthly
- AI reads
- Our server logs, IP-verified every 6 hours
- AI visibility
- Measured 2026-10-01
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition